Skip to main content

Paracel Closes Down Operations

NEW YORK, Sept. 29 (GenomeWeb News) - Paracel, a Celera Genomics subsidiary, has closed down its operations, the company said yesterday.

 

In a notice posted on its website, the Pasadena, Calif.-based bioinformatics tool provider said that as of Sept. 28, it has discontinued all operations except for ongoing support to its current contract customers.

 

No further information was immediately available from Paracel.

 

Two years ago, GenomeWeb News reported that Paracel's future as a Celera unit was uncertain. The company has been providing genome researchers with bioinformatics hardware systems, including GeneMatcher and BlastMachine.

 

Paracel was founded in 1992 to commercialize data-filtering technology developed by TRW for government applications. Together with researchers from Caltech and Applied Biosystems, the firm programmed the FDF system for genomic data analysis.

The company became a wholly owned subsidiary of Applera after Celera acquired it in a stock-for-stock transaction in June 2000. The company is based in Pasadena, Calif., and has offices in San Jose, Calif., Columbia, Md., and the UK.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.